Overview

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Status:
Completed

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma

Treatments:

Certolizumab Pegol
Methotrexate